SCHEMBL10075813

SCHEMBL10075813

C/C(=N\OC(=O)CCC(=O)O)C(=O)c1ccc(Sc2ccc(C(=O)OCCO)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.33
ALDH1A1 P00352 5/20 0.33
LMNA P02545 4/20 0.33
HPGD P15428 3/20 0.33
KDM4E B2RXH2 2/20 0.32
GAA P10253 1/20 0.32
TDP1 Q9NUW8 3/20 0.32
MAPT P10636 2/20 0.32
SLC7A5 Q01650 1/20 0.32
ESR1 P03372 2/20 0.32
TSHR P16473 2/20 0.32
CHRM1 P11229 1/20 0.32
SLC6A2 P23975 1/20 0.32
KDR P35968 1/20 0.32
PTGIR P43119 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10075709 0.86 L3MBTL1 (0.43) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL10131751 0.86 L3MBTL1 (0.37) L3MBTL1KMT2ALMNATDP1MAPT
SCHEMBL10075808 0.84 L3MBTL1 (0.41) L3MBTL1KMT2AHTTALDH1A1LMNA
SCHEMBL10075721 0.83 L3MBTL1 (0.41) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL10075714 0.81 L3MBTL1 (0.39) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL10075753 0.80 L3MBTL1 (0.43) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL10075804 0.80 L3MBTL1 (0.43) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL12643232 0.80 SMN1; SMN2 (0.40) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL20709809 0.79 SLC7A5 (0.38) L3MBTL1KMT2AALDH1A1LMNAHPGD
SCHEMBL10075711 0.79 L3MBTL1 (0.41) L3MBTL1KMT2AALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586827-B1 CURABLE RESIN COMPOSITION ADEKA CORP (JP) 2017-12-27 EP disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
EP-2586827-A1 CURABLE RESIN COMPOSITION Adeka Corporation (JP) 2013-05-01 EP disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
EP-2327689-A1 Oxime ester compound and photopolymerization initiator containing the same Adeka Corporation (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME OXER1, OR10J3, CDK11B L3MBTL1 1628/4885KMT2A 3531/4885HTT 4780/4885
US-20120115972-A1 CURING RESIN COMPOSITION LTA, LOXL1, PLOD2 L3MBTL1 228/4885KMT2A 247/4885HTT 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.